Thursday, June 19, 2025

Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance

 - Streamlining operations and reducing risk in asset integrity management –


 


(BUSINESS WIRE)--Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries.


ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for leaks and machinery issues. It is the result of a two-year collaborative effort within Shell, which combined machine vision strategy with deep capabilities in the field of integrity management, remote site inspection, and corrosion management.


OpreX Robot Management Core is a key product in Yokogawa’s robot solutions. The software helps customers maintain their facilities in a safer and more efficient manner by integrating the management of various types of robots that perform plant maintenance tasks conventionally carried out by humans. When connected to a plant’s control and safety systems, the data acquired can be used to issue instructions to robots, thus enabling the first step to be taken toward autonomous plant operations. The addition of Shell’s ORE technology will significantly increase the number of use cases available to customers through OpreX Robot Management Core.


Moving forward, Yokogawa robotics operations will deploy at two Shell facilities as a pilot into how robotics and drones can deliver value through efficiencies in plant monitoring and maintenance.


This collaboration is the first key milestone for Yokogawa working alongside Shell in the collaboration space at the Energy Transition Campus Amsterdam, which was created by Shell in 2022 to provide a platform for collaboration between companies, societal organisations, governments, and universities to work on tomorrow’s energy solutions. Shell and Yokogawa have also agreed to collaborate on an aligned R&D roadmap to further develop and enhance the machine vision technology, ensuring continuous innovation and improvement. This collaboration underscores both companies' commitment to providing cutting-edge solutions to the energy and industrial sectors.


Masaharu Maeda, Yokogawa Electric vice president, executive officer, and head of the company’s Solutions Business Division, stated, “We are very excited to be working with Shell on this key technology field that promises to address the workforce challenges facing plant owners by significantly improving the efficiency of rounds in the field, while also reducing the inherent risk to operators. We look forward to making it available to industrial facility owners globally in the near future and contributing to safer and more efficient workplaces.”


“Shell & Yokogawa have a proud history of developing together to enable advanced automation solutions for our sites. With this agreement, we are taking our relationship to the next level. Robotics solutions combined with AI provide the potential to create a step change in productivity and safety,” said Gerben de Jong, CIO for Shell Integrated Gas, Upstream and Projects & Technology.


For More Information


Robot and Drone Technology:

https://www.yokogawa.com/solutions/featured-topics/robot-and-drone-technology/


About Yokogawa


Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.

Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,000+ employees in a global network of 128 companies spanning 62 countries.

For more information, visit www.yokogawa.com


The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617976629/en/



Permalink

https://www.aetoswire.com/en/news/1806202547458


Contacts

Media enquiries

PR Department

Integrated Communications Center

Yokogawa Electric Corporation

Yokogawa-pr@cs.jp.yokogawa.com


 

LambdaTest Wins 2025 Digital Innovator Award from Intellyx

 Recognition highlights LambdaTest’s role in accelerating digital transformation through intelligent testing innovation

(BUSINESS WIRE) -- LambdaTest, a unified agentic AI and cloud engineering platform, has been recognized with the prestigious 2025 Intellyx Digital Innovator Award, honoring its impact on enterprise digital transformation and continued leadership in modern testing solutions.

Now in its 11th year, Intellyx is the only analyst firm dedicated to digital transformation. The Intellyx Digital Innovator Awards spotlight select vendors who are redefining the enterprise IT landscape.

“We’re honoured to receive the Intellyx Digital Innovator Award,” said Asad Khan, Co-Founder and CEO of LambdaTest. “This recognition highlights our commitment to helping development teams ship quality code faster through intelligent automation, AI-driven testing insights, and seamless orchestration across the software development lifecycle.”

LambdaTest is an AI-native, omnichannel software quality platform that empowers businesses to accelerate time to market through intelligent, cloud-based test authoring, orchestration, and execution. With over 15,000 customers and 2.3 million+ users across 130+ countries, LambdaTest is the trusted choice for modern software testing.

For more information about the award and the full list of winners, visit the 2025 Intellyx Digital Innovator Awards page.

About LambdaTest

LambdaTest is an AI-native, omnichannel software quality platform that empowers businesses to accelerate time to market through intelligent, cloud-based test authoring, orchestration, and execution. With over 15,000 customers and 2.3 million+ users across 130+ countries, LambdaTest is the trusted choice for modern software testing.

  • Browser & App Testing Cloud: Enables manual and automated testing of web and mobile apps across 10,000+ browsers, real devices, and OS environments, ensuring cross-platform consistency.

  • HyperExecute: An AI-native test execution and orchestration cloud that runs tests up to 70% faster than traditional grids, offering smart test distribution, automatic retries, real-time logs, and seamless CI/CD integration.

  • KaneAI: The world’s first GenAI-native testing agent, leveraging LLMs for effortless test creation, intelligent automation, and self-evolving test execution. It integrates directly with Jira, Slack, GitHub, and other DevOps tools.

For more information, please visit https://lambdatest.com

 



Kinaxis Announces Results of Voting at Annual Meeting of Shareholders

 OTTAWA, Ontario - Wednesday, 18. June 2025 AETOSWire Print 


(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain orchestration, received approval for all resolutions put forward to shareholders at today’s Annual Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated April 28, 2025 (the “Circular”).


1. Election of Directors


Shareholders voted to elect all seven directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed.


Name of Nominee


Total Number of Votes For


Percentage of Votes For


Total Number of Votes Against


Percentage of Votes Against


Robert Courteau


22,065,236


95.74%


982,599


4.26%


Gillian (Jill) Denham


22,357,176


97.00%


690,659


3.00%


José Alberto Duarte


22,430,093


97.32%


617,742


2.68%


Lynn Loewen


22,702,703


98.50%


345,163


1.50%


Angel Mendez


22,338,977


96.92%


708,858


3.08%


Pamela Passman


22,394,586


97.17%


653,249


2.83%


Kelly Thomas


22,562,248


97.89%


485,588


2.11%


2. Appointment of Auditors


Shareholders voted to approve the appointment of KPMG LLP as auditors for Kinaxis and hold office until the close of the next annual meeting of shareholders or until a successor is appointed.


Total Number of Votes For


Percentage of Votes For


Total Number of Votes Withheld


Percentage of Votes Withheld


22,811,181


98.58%


328,559


1.42%


3. Advisory Vote on Approach to Executive Pay


Shareholders voted to accept the Company’s approach to executive compensation as described in the Circular.


Total Number of Votes For


Percentage of Votes For


Total Number of Votes Against


Percentage of Votes Against


20,455,842


88.75%


2,592,194


11.25%


For further details on each of the above matters, please refer to the Circular available under Kinaxis’ profile on the System for Electronic Document Analysis and Retrieval (SEDAR+) at www.sedarplus.ca, or in the Financials section of the Company’s Investor Relations website.


Final voting results on all matters voted on at the AGM will be filed on SEDAR+ at www.sedarplus.com.


About Kinaxis


Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.


Source: Kinaxis Inc


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617983181/en/



Permalink

https://www.aetoswire.com/en/news/54277688


Contacts

 

Media Relations

Matt Tatham | Kinaxis

mtatham@kinaxis.com

+1 917-446-7227


Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

+1 613-907-7613

Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time

 



 (BUSINESS WIRE)-- Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world.

Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time

Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink.

“This partnership is about removing friction and delivering real business value,” said Vladimir Jandreski, Chief Product Officer at Ververica. “Aiven users running Kafka can now seamlessly step into real-time stream processing with Apache Flink® through our enterprise-grade platform. And for Ververica users, Aiven simplifies operations with a proven managed service. Together, we’re lowering the barrier to scalable, high-performance streaming.”

"Partnering with Ververica gives our customers direct access to enterprise-grade stream processing, powered by the creators of Apache Flink," said Conor Forde, SVP Go To Market at Aiven. "Together, we’re making it easier to build scalable, real-time applications with expert support and unlock more value from streaming data, faster."

This marks the first step forward in further collaboration to position Aiven and Ververica in leading the way forward for empowering enterprises to create value from their data.

About Ververica

Ververica, the original creators of Apache Flink®, empowers businesses with high-performance data streaming and processing solutions. Streamlining operations, developer efficiency, and enabling customers to solve real-time use cases reliably and securely. Ververica’s advanced Streaming Data Platform, powered by its cloud native VERA engine, revolutionizes Apache Flink®, making it easy for organizations to harness data insights at scale. With Ververica, customers can meet any business SLA, leveraging advanced data streaming and processing capabilities in real-time or on the lakehouse. Ververica enables businesses to connect, process, govern, and analyze data, across infinite use cases, with flexible deployment options, including public cloud, private cloud, or on-premise environments. Discover more at ververica.com.

About Aiven

Aiven is a global open source data platform company, helping organizations drive more value from their data. As a trusted foundation to power innovation, Aiven’s comprehensive cloud data platform combines the tools to stream, manage and analyse data, simply, securely, and rapidly. Aiven is trusted by customers globally to create next-gen applications with confidence. Learn more at aiven.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617806011/en/



Contacts

Media Contact:
Sarah Evans
Zen Media
sarah@zenmedia.com


SES Successfully Prices €1 Billion Dual-Tranche Bond Offering with Strong 5.5x Oversubscription

 (BUSINESS WIRE)--NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (THE UNITED STATES), OR TO ANY US PERSON (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933), OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.


SES S.A. today announced the successful launch and pricing of a dual-tranche note offering in which the company has agreed to sell senior unsecured fixed rate notes under its €5,500,000,000 EMTN Programme (the "Notes"). Settlement is expected to take place on 24 June 2025:


EUR 500 million of Notes will bear a coupon of 4.125% due in 2030.

EUR 500 million of Notes will bear a coupon of 4.875% due in 2033.

SES is rated Baa3, negative outlook by Moody’s and BBB, negative outlook by Fitch.


SES shall apply the net proceeds of the Notes towards its general corporate purposes, including, without limitation (i) financing all or part of the purchase price of the acquisition of Intelsat Holdings S.A. (“Intelsat” and Intelsat and its subsidiaries being the “Intelsat Group”) (the “Acquisition”) (including the payment of fees, costs and expenses in relation to the Acquisition) and/or (ii) refinancing existing indebtedness of the Group and/or (following closing of the Acquisition) the Intelsat Group.


Promptly following the Issue Date, SES intends to cancel the bridge facility in relation to the Acquisition in an amount at least equal to the net proceeds of the Notes.


SES also announces that, to further optimise the debt structure of the combined entity following the Acquisition, it intends to redeem (in aggregate) up to US$ 3 billion of the 6.500% First Lien Senior Secured Notes due 2030 issued by Intelsat Jackson Holdings SA ("SSNs") on, and conditional upon, closing of the Acquisition and settlement of the Notes. This will be achieved by the redemption of part or all of the SSNs in accordance with the optional redemption provisions governing the SSNs. Additionally, SES may from time to time conduct open market purchases of the SSNs.


Deutsche Bank and Morgan Stanley acted as Global Coordinators and Joint Bookrunners, together with Goldman Sachs International, ING, J.P. Morgan, Société Générale as Joint Bookrunners. The settlement is scheduled for 24 June 2025 and application has been made for the Notes to be listed on the Luxembourg Stock Exchange. The securities were placed with a broad range of institutional investors across Europe and Americas region.


The successful, pricing of €1 billion dual-tranche bond offering, provides SES enhanced financial flexibility which in combination with an existing strong balance sheet gives SES sufficient liquidity to cover upcoming maturities. This reflects SES’s disciplined financial policy and commitment to investment grade metrics and sets the combined company on a strong footing for long-term balance sheet strength.


Sandeep Jalan, outgoing CFO of SES commented: “We are delighted with the successful conclusion of this bond note offering, which reflects the market’s strong confidence in SES as a quality investment grade credit. The impressive 5.5x oversubscription of the order book demonstrates the deep commitment of investors to SES’s strategic vision and long-term value creation. With the anticipated closing of the Intelsat transaction in H2 of 2025, this marks the final step in our market access related to the financing of the Intelsat acquisition—an important milestone in our growth journey.”


Follow us on:


Twitter | Facebook | YouTube | LinkedIn | Instagram


Read our Blogs >


Visit the Media Gallery >


About SES


SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617403124/en/



Permalink

https://aetoswire.com/en/news/1806202547452


Contacts

Christian Kern

Investor Relations

Tel: +352 710 725 7787

christian.kern@ses.com


Suzanne Ong

Communications

Tel. +352 710 725 500

suzanne.ong@ses.com


AtkinsRéalis Expands Award-Winning School of the Future Initiative Across UAE Schools

 AtkinsRéalis (TSX: ATRL), a world-class design, engineering services and nuclear company, has expanded its School of the Future initiative for the second consecutive year in the UAE. The initiative, which introduces students to sustainability, engineering, and technology through experiential learning, brought together participants from four leading schools for the 2025 finals held at Dubai English Speaking College (DESS) on 14 May.


Originally launched in the UK, the School of the Future engages students aged 14 to 16 in designing sustainable school campuses. This year’s UAE edition welcomed teams from Repton School, Jumeirah College, JESS Dubai, and Dubai English Speaking College (DESS). The initiative challenges students to think critically about environmental, social, and technological aspects of sustainability while encouraging them to create forward-thinking campus concepts built for the future.


“As this initiative continues to grow year on year, we are proud to see the strong interest and engagement from both students and educators alike in the UAE,” said Campbell Gray, CEO, Middle East, AtkinsRéalis. “By expanding the programme across more schools in the region, we hope to continue strengthening the link between industry and education by helping young people become future-ready leaders in sustainability and innovation.”


Throughout this project, students were mentored by AtkinsRéalis STEM Ambassadors and guided through a multi-dimensional learning journey. Teams developed sustainable, data-driven design proposals by leveraging AI and prioritised renewable energy, smart infrastructure, and water conservation, while also considering the social impact of their schools on surrounding communities.


The event concluded with a showcase held at DESS, where student teams presented their ideas to a panel of judges from different backgrounds. Presentations were evaluated based on innovation, collaboration, and the practical application of sustainable principles.


"Partnering with Atkins Realis for the School of the Future Competition has been a powerful opportunity to bring industry and education together,” said Laura Reidy, Head of Information, Advice and Guidance, Dubai English Speaking School (DESS). “Our students were inspired by the challenge to think big, design boldly, and reimagine what learning could look like for future generations. We're proud to be part of a collaboration that champions innovation, sustainability, and student voices."


With growing interest across the region, AtkinsRéalis plans to continue expanding the initiative to reach more schools and students in the Middle East. The initiative aligns with the company’s long-term sustainability strategy and contributes directly to the United Nations Sustainable Development Goals, particularly those focused on education and sustainable communities.


For more information about the School of the Future, visit https://www.atkinsrealis.com/en/engineering-better-future/beyond-engineering/school-of-the-future


About AtkinsRéalis


Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at www.atkinsrealis.com or follow us on LinkedIn.



Permalink

https://www.aetoswire.com/en/news/1906202547479


Contacts

For more information, please contact:


Praveena Rajasekar


Senior Advisor, External Communications


praveena.rajasekar@atkinsrealis.com

Experian Accelerates Migration to AWS to Drive Innovation with Generative AI

 Global data and technology leader expands its cloud footprint to enhance performance and reliability, using AWS analytics and AI capabilities to give financial organizations access to real-time intelligence


(BUSINESS WIRE) -- Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Experian, a global data and technology company, is embarking on the next phase of its cloud migration and has selected AWS as its preferred cloud. By leveraging AWS’s advanced cloud capabilities, Experian can provide faster, more scalable solutions that empower clients with deeper insights and more secure data services.


Experian's cloud first strategy, in partnership with AWS, accelerates innovation by enhancing performance, scalability, and reliability, while enabling the company to better serve its clients with innovative products and solutions. By migrating off mainframe computers and moving multiple on-premises servers to the cloud, Experian is able to centralize its technology platforms in the cloud and use its data to drive deeper insights and predictive capabilities. Leveraging AWS's robust infrastructure, Experian can quickly adapt to evolving client needs, ensuring secure and efficient data handling.


As part of this new 10-year strategic agreement, Experian has selected AWS as their strategic partner for generative artificial intelligence (AI), developing more than 100 generative AI use-cases. This collaboration will drive operational efficiency, democratize data technologies for employees, and develop new credit and financial analytics offerings. With the integration of generative AI, Experian is streamlining the complex process of database migrations, automating and optimizing the transfer of vast datasets, reducing downtime, improving data accuracy, and further solidifying its position as a leader in the global data and technology industry.


“AWS is delighted to partner with Experian to unlock opportunities that drive innovation, increase agility, and accelerate their modernization,” said Scott Mullins, Managing Director, Worldwide Financial Services at AWS. “As they build intelligent data platforms, develop cutting-edge applications with generative AI, and gain real-time insights, Experian is demonstrating how organizations can reinvent their operations while maintaining security, compliance, and resilience at scale.”


"Our initial migrations gave us enhanced performance, security, and reliability, making it an easy choice to take that a step farther and embrace a cloud-first strategy," said Rodrigo Rodrigues, Chief Technology Officer at Experian. "Having our data readily available in the cloud sets us up to invest in new capabilities like generative AI and advance products and solutions for our clients with proven security. By moving to AWS, we've reduced our data processing time by 60%, improved our ability to launch new products from months to weeks, and can now analyze credit data in real-time to better serve our customers."


By leveraging AWS's robust security controls and advanced threat detection and mitigation capabilities, Experian can ensure the highest levels of data protection and regulatory compliance. Together, Experian and AWS are committed to creating transformative experiences that benefit both businesses and consumers, fostering growth, trust, and innovation across the digital landscape.


About Amazon Web Services


Since 2006, Amazon Web Services has been the world’s most comprehensive and broadly adopted cloud. AWS has been continually expanding its services to support virtually any workload, and it now has more than 240 fully featured services for compute, storage, databases, networking, analytics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, media, and application development, deployment, and management from 117 Availability Zones within 37 geographic regions, with announced plans for 13 more Availability Zones and four more AWS Regions in Chile, New Zealand, the Kingdom of Saudi Arabia, and the AWS European Sovereign Cloud. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visit aws.amazon.com.


About Amazon


Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.


About Experian


Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money.


We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.


We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 23,300 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250619029263/en/



Permalink

https://www.aetoswire.com/en/news/1906202547488


Contacts

Media Contacts:


AWS:

Naomi Little

njlittle@amazon.com

1 771 233 2089


Experian:

Scott Anderson

Scott.n.anderson@experian.com

1 949 531 1783

New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X

KYOTO, Japan - Thursday, 19. June 2025

The new BLM15VM series is ideal for automotive powertrains and safety applications. It supports high frequencies. 1000Ω (Typ.) @5.9GHz. With its compact 0402-inch size (1.0×0.5mm) can operate at temperatures ranging from -55 to 150°C. And it is compliant with AEC-Q200.

(BUSINESS WIRE) -- Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025.

In recent years, the use of high-frequency wireless communication in the automotive sector has increased. It is primarily used for content distribution for navigation, audio and other infotainment systems. Improving sensitivity and noise suppression in these advanced high-frequency communication systems becomes mission critical to support the connected car for ADAS (Advanced Driver Assistance Systems) and eventually autonomous driving.

RF inductors typically used for noise suppression in sub-6GHz communication have a narrow frequency band at high impedance, making it necessary to select components that match the noise frequency band. With its broad high-frequency band at high impedance, the BLM15VM series allows easy noise suppression across multiple frequency bands using just one product. Even at 5.9GHz, the chip ferrite beads within the series will typically attain impedance values of 1000Ω.

By enabling error-free high-frequency communication, which is crucial for autonomous driving, the BLM15VM series significantly improves reception sensitivity in V2X communication in the 5.9GHz bands for autonomous driving and stable operation of dedicated short-range communication (DSRC) based control systems, operating in the 5.8GHz band, for improved road safety. Additionally, since Wi-Fi 6E and Wi-Fi 7, the communication standards for wireless LAN, also use the sub-6GHz band, this product can improve sensitivity and suppress noise in consumer communication devices.

The AEC-Q200-compliant BLM15VM series of chip ferrite beads from Murata supports operating temperatures between -55 to 150°C and is supplied in a compact 0402-inch size (1.0×0.5mm). Murata is committed to expanding its lineup to meet market needs.

For more details about the Product, see the ‘BLM15VM150BH1’ page.
Requests of free small-quantity samples are available here.
For inquiries regarding the product, click here.

Editor’s Notes
According to the Company's research. This is the world's first product that removes noise in high-frequency communication (including Sub6 bands) for C-V2X, as of June 18, 2025.

About Murata
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618511573/en/


Permalink
https://www.aetoswire.com/en/news/1906202547474

Contacts
For more information, please contact:
Murata Manufacturing Co., Ltd.
Keisuke Tsuboi, prsec_mmc@murata.com
Corporate Communications Department

LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

 (BUSINESS WIRE)--Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.


The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival.3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3-ITD identifies AML patients in remission who are most likely to relapse or experience poor survival.3,4,5


With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.


“We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,” said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. “This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we’re further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.”


LabPMM’s NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM’s full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.


About Invivoscribe


Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.


Falini, B. et al. Blood. 2020; 136(15):1707–1721.

Kelemen, K. Life. 2022; 12(1): 109.

Dillon, L. et al. JAMA. 2023; 329(9):745-755

Dillon, L. et al. JAMA Oncology. 2024; 10(8)1104-1110

Levis, M. et al. Blood. 2025; 145(19):2138-2148.

 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617961412/en/



Permalink

https://www.aetoswire.com/en/news/1806202547456


Contacts

inquiry@invivoscribe.com

DDC Enterprise Announces Up to $528 Million Raise to Accelerate Bitcoin Treasury Strategy

 NEW YORK - Tuesday, 17. June 2025 AETOSWire 



Landmark Funding Dedicated Exclusively to Bitcoin Acquisition Positions DDC to Become a Global Leader in Bitcoin Holdings


(BUSINESS WIRE)--DDC Enterprise Limited (NYSE: DDC) (“DDC” or the “Company”) today announced it has entered into three securities purchase agreements for a total of up to $528 million of gross proceeds to the Company, before placement agent fees and offering expenses. Investors include Anson Funds, Animoca Brands, Kenetic Capital, QCP Capital, and a network of leading institutional funds and individual Bitcoin investors. Substantially all of the capital raise will be dedicated to expanding the Company’s Bitcoin treasury. This transformative financing, among the largest single-purpose Bitcoin raises by any NYSE-listed company, is expected to accelerate DDC's mission to establish one of the most valuable corporate Bitcoin holdings.


Strategic Funding Structure: Institutional Confidence at Scale


$26 Million Equity PIPE Investment

The Company has entered into subscription agreements with premier investors including Animoca Brands, Kenetic Capital, QCP Capital, Jack Liu, Matthew Liu (Co-Founder, Origin Protocol), and other leading institutional funds and individual Bitcoin investors. Subject to standard closing conditions, DDC expects to issue up to 2,435,169 Class A Ordinary shares at an average price of $10.30 per share. The shares will be restricted for 180-days.

 

$300 Million Convertible Secured Note and $2 Million Equity Private Placement

With Anson Funds as the investor, an institutional investment firm with offices in the United States and Canada, the convertible secured note accrues no interest and will mature in 24 months. Pursuant to the Facility, the Company will issue a note in the aggregate principal amount of $25 million as its first tranche, with additional capacity of up to $275 million available in subsequent drawdowns upon mutual agreement of the parties. Anson Funds is also purchasing 307,693 Class A Ordinary shares for $2 million in a concurrent private placement.

 

$200 Million Equity Line

The $200 million equity line of credit (“ELOC”), also secured with Anson Funds, is designed to offer DDC maximum flexibility in accessing capital for dedicated BTC stacking. With the ELOC, upon its future commencement following registration, the Company can optimize market timing and can consistently make BTC purchases over time at management discretion.

Substantially all of the gross proceeds from the financings will be deployed to acquire Bitcoin.


Statement from Norma Chu, Founder, Chairwoman & CEO of DDC Enterprise


"Today is a defining moment for DDC Enterprise and our shareholders. This capital commitment of up to $528 million, backed by respected institutions from both traditional finance and the digital asset frontier, represents a strong mandate to execute an ambitious corporate Bitcoin accumulation strategy globally. Our vision is unequivocal: we are building the world's most valuable Bitcoin treasury.”


Ms. Chu, continued, “This funding is expected to propel DDC into one of the top global corporate Bitcoin holders. This investment by Anson Funds and the group of PIPE investors is a resounding validation of Bitcoin's important role in future corporate balance sheets. At DDC, we will deploy this capital with institutional discipline and unwavering conviction, cementing our position as the premier bridge between global capital markets and the Bitcoin ecosystem. DDC Enterprise is strongly positioned as the definitive publicly-traded vehicle for concentrated Bitcoin exposure and value creation. My focus will be on growing our BTC treasury and delivering attractive BTC yield consistently for our shareholders."


Maxim Group LLC acted as the exclusive financial advisor in connection with the offering. The closings of the financings are subject to the satisfaction of customary closing conditions.


This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


About DDC Enterprise


DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing an aggressive accumulation strategy. While continuing to grow its portfolio of culinary brands – including DayDayCook, Nona Lim, and Yai's Thai – DDC is now at the vanguard of public companies integrating Bitcoin into their financial architecture.


Caution Regarding Forward-Looking Statements


Certain statements in this announcement are forward-looking statements.


Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. Examples of forward-looking statements include those related to business prospects, accumulation of Bitcoin, and the Company’s goals and future activity under the financing transactions described above, including the statements on the closings of the offerings and the satisfaction of closing conditions and use of proceeds in the offerings. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 20-F, 6-K and other reports, including a Form 6-K which with copies of the definitive documents related to the above transactions, to be filed with the Securities and Exchange Commission (“SEC”) and available at www.sec.gov. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250616739727/en/



Permalink

https://www.aetoswire.com/en/news/54276433


Contacts

 

For Bitcoin Investor Relations:

Yujia Zhai | ddc@orangegroupadvisors.com

Media: pr@daydaycook.com

NTT DATA Research Reveals C-Suite Misalignment Over GenAI Adoption

LONDON - Tuesday, 17. June 2025


    Nearly half of CISOs have negative sentiments about GenAI rollouts, despite CEO optimism
    CEOs are all-in on GenAI, but CISOs warn that security gaps and aging infrastructure are holding back progress
    Alignment requires stronger governance and dedicated investment

 

(BUSINESS WIRE)--NTT DATA, a global leader in digital business and technology services, today launched its new report, “The AI Security Balancing Act: From Risk to Innovation,” highlighting the opportunities and risks AI presents in cybersecurity. The findings show a misalignment among C-Suite leaders when it comes to business goals and operational readiness for GenAI deployment.

The report, which includes data from an NTT DATA survey of more than 2,300 senior GenAI decision makers, comprising 1,500 *C-Suite leaders across 34 countries, found that while CEOs and business leaders are committed to GenAI adoption, CISOs and operational leaders lack the necessary guidance, clarity and resources to fully address security risks and infrastructure challenges associated with deployment.

The C-Suite disconnect

Nearly all (99%) C-Suite executives are planning further GenAI investments over the next two years, with 67% of CEOs planning significant commitments.

In parallel, 95% of CIOs and CTOs report that GenAI has already driven, or will drive, greater cybersecurity investments, with organizations ranking improved security as one of the top three business benefits realized from GenAI deployment in the last 12 months.

Yet, even with this optimism, there is a notable disconnect between strategic ambitions and operational execution with nearly half of CISOs (45%) expressing negative sentiments toward GenAI adoption. More than half (54%) of CISOs say internal guidelines or policies on GenAI responsibility are unclear, yet only 20% of CEOs share the same concern – revealing a stark gap in executive alignment.

Despite feeling cautious about the deployment of GenAI, security teams still acknowledge its business value. In fact, 81% of senior IT security leaders with negative sentiments still agree GenAI will boost efficiency and impact the bottom-line.

Organizational operations not ready for GenAI

NTT DATA’s research further reveals a critical gap between leadership’s vision and the capabilities of their teams. While 97% of CISOs identify as decision makers on GenAI, 69% acknowledge that their teams lack the necessary skills to work with the technology.

In addition, only 38% of CISOs say their GenAI and cybersecurity strategies are aligned compared to 51% of CEOs.

Adding to the complexity, 72% of organizations surveyed still lack a formal GenAI usage policy and just 24% of CISOs strongly agree that their organization has a robust framework for balancing risk with value creation.

Legacy tech limiting GenAI adoption

Beyond internal misalignment, 88% of security leaders said legacy infrastructure is greatly affecting business agility and GenAI readiness, with modernizing IoT, 5G and edge computing identified as essential for future progress.

To navigate these obstacles, 64% of CISOs are prioritizing co-innovation with strategic IT partners rather than relying on standalone AI solutions. Notably, security leaders #1 top criteria when assessing GenAI technology partners is end-to-end GenAI service offerings.

"As organizations accelerate GenAI adoption, cybersecurity must be embedded from the outset to reinforce resilience. While CEOs champion innovation, ensuring seamless collaboration between cybersecurity and business strategy is critical to mitigating emerging risks," said Sheetal Mehta, Senior Vice President and Global Head of Cybersecurity at NTT DATA, Inc. "A secure and scalable approach to GenAI requires proactive alignment, modern infrastructure and trusted co-innovation to protect enterprises from emerging threats while unlocking AI’s full potential."

"Collaboration is highly valued by line-of-business leaders in their relationships with CISOs. However, disconnects remain, with gaps between the organization's desired risk posture and its current cybersecurity capabilities,” said Craig Robinson, Research Vice President, Security Services at IDC. “While the use of GenAI clearly provides benefits to the enterprise, CISOs and Global Risk and Compliance leaders struggle to communicate the need for proper governance and guardrails, making alignment with business leaders essential for implementation."

Download the full report here, and visit our website to learn more about NTT DATA’s AI services for cybersecurity.

Methodology

The report is based on insights from 2,300 senior GenAI decision-makers across 34 countries. 68% of respondents were from the C-suite, including CEOs, CISOs, CIOs, CTOs, CDOs, COOs, CCOs, CFOs, CHROs, and CSEs. 27% held Vice President, Head of, or Director-level roles, while 5% were senior managers or specialists. This research was independently conducted for NTT DATA by Jigsaw Research, a global strategic insight agency.

About NTT DATA

NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at nttdata.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250617433963/en/

Permalink
https://www.aetoswire.com/en/news/1706202547444

Contacts

Media Contact
Lori Bosio
lori.bosio@nttdata.com

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years


 ZUG, Switzerland 

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1

Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3

This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4

 


(BUSINESS WIRE)--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/


 


“These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.”


 


BALDO SCASSELLATI SFORZOLINI, M.D., PHD.


GLOBAL HEAD OF RESEARCH & DEVELOPMENT


GALDERMA


 


 


Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients’ quality of life.5-7 Nemluvio is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31.8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis.8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment.9,10


The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials.1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years.1 At Week 100 in evaluable patients, the interim analysis shows that:


More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale1

At least 80% achieved 76‑100% healed pruriginous lesions1

Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator’s Global Assessment score1

Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date.1


 


“These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I’m thrilled to be able to see its meaningful impact in the real world.”


 


PROF. SONJA STÄNDER

LEAD INVESTIGATOR OF THE OLYMPIA STUDIES IN EUROPE

UNIVERSITY HOSPITAL MUNSTER, GERMANY


 


 


This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years.4


Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing.


Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea.


More details on Galderma’s scientific presentations at ICD can be found here.


About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.12,13


About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence.11,14,15


About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


References


Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy.

ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025

ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025

Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States.

Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183

Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013

Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025

Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025

Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2

Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025

Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025

Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009

Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi: 10.1016/j.jid.2019.07.697

 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617336479/en/



Permalink

https://www.aetoswire.com/en/news/1806202547455


Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62


Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

SINOVAC Announces New Board Member

 BEIJING - Wednesday, 18. June 2025 AETOSWire  


(BUSINESS WIRE) -- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the “Board”) and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang’s resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board.


Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world’s largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team’s biotech and emerging markets efforts. He has been responsible for overseeing the firm’s public equity investments in China since 2009 and the firm’s investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School.


Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu.


About SINOVAC


Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.


SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.


The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.


SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.


SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.


For more information, please visit the Company’s website at www.sinovac.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250617453752/en/



Permalink

https://www.aetoswire.com/en/news/1806202547465


Contacts

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279 9779

Email: ir@sinovac.com

Wednesday, June 18, 2025

Bureau Veritas Accelerates its LEAP | 28 Strategy Execution and Evolves its Executive Committee


 PARIS

(BUSINESS WIRE) -- Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness.


Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People - and is now reaching an important stage requiring an evolution of the operating model. The new structure will empower the regions with scalable Product Lines, enabling global offers development, unlocking greater cross-selling opportunities, and driving growth and profitability.


The current six operating geographical Regions will be reorganized into four greater Regions: Americas, Europe, Asia Pacific, Middle East Caspian & Africa. The Product lines will be managed under three executive committee members who will lead: Industrials and Commodities, Urbanization and Assurance, and Consumer Products Services. These groupings at the executive committee level are aligned with customer workflows and market needs.


Considering the company ambition to scale performance programs across all the Regions and Product lines, a Chief Performance Officer and Executive Committee member role will be dedicated to lead the LEAP I 28 performance pillar and the overall optimization of key performance functions of operational excellence & performance, and sales & marketing. This role will drive the design, governance, and overall implementation and monitoring of these programs in coordination with other stakeholders across the organization.


All other Business and Support Functions will remain under their current leaders.


Hinda Gharbi, Chief Executive Officer of Bureau Veritas comments: “By directly connecting Product Lines to a simplified regional structure, we are strengthening our regional expertise and building deeper relations with our customers. This organization will also allow us to create more agility as we accelerate the execution of our LEAP | 28 strategy.


This new organization will leverage scale, benefit from a well-defined structure, thus speeding up decision making, performance impact, and innovation. I fully trust our Bureau Veritas Executive team to mobilize the entire organization to achieve our vision and deliver on our ambition.”


***


The transition period will extend from July 1st to the end of August 2025.

Effective September 1st 2025, the Group Executive Committee will be structured and composed as follows:


Regions:


Europe: Executive Vice-President > Vincent Bourdil


Middle East Caspian & Africa: Executive Vice-President > Khurram Majeed


Asia Pacific: Executive Vice-President > Surachet Tanwongsval


Americas: Executive Vice-President to be appointed before year end


Product Lines:


Industrials and Commodities: Executive Vice-President > Matthieu Gondallier De Tugny


Urbanization and Assurance: Executive Vice-President > Marc Roussel


Consumer Products Services: Executive Vice-President > Catherine Chen


Business Functions:


Corporate development & sustainability: Executive Vice-President > Juliano Cardoso


Chief Performance Officer: Executive Vice-President > Laurent Louail


Chief Digital & Innovation Officer: Executive Vice-President DxT (Digital & Technology) > Philipp Karmires


Support Functions:


Chief Financial Officer: Executive Vice-President > François Chabas


Chief People Officer: Executive Vice-President > Maria Lorente Fraguas


Legal affairs & Internal Audit: Executive Vice-President > Beatrice Place-Faget


***


About Bureau Veritas


Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.

Created in 1828, Bureau Veritas’ 84,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.

Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.

For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.


***


Biographies:


Vincent Bourdil, appointed Executive Vice-President, Europe, joined Bureau Veritas in 2016 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Global Business Lines & Performance before becoming Executive Vice-President, Commodities, Industry & Facilities, Southwest Europe.


Khurram Majeed remains Executive Vice-President, Middle East, Caspian & Africa. He is a seasoned industry leader with over 23 years of senior management experience across energy, oil & gas, and other sectors. Khurram joined Bureau Veritas in 2024 as Executive Vice-President, Middle East, Caspian & Africa.


Surachet Tanwongswal remains Executive Vice-President Asia Pacific. He joined Bureau Veritas in 2024 as Executive Vice-President for Commodities, Industry & Facilities in Asia Pacific. Prior to this, Surachet held leadership roles at Ecolab and other global B2B companies.


Matthieu Gondallier de Tugny, appointed Executive Vice-President Industrials and Commodities, joined Bureau Veritas in 1994 and has held various technical, operational, and leadership roles in Marine & Offshore. His most recent role was Executive Vice-President, Marine & Offshore.


Marc Roussel, appointed Executive Vice-President Urbanization and Assurance, joined Bureau Veritas in 2015 and has held multiple leadership roles across the company. His most recent role was Executive Vice-president, Commodities, Industry & Facilities, France.


Catherine Chen remains Executive Vice-President Consumer Products Services. She joined Bureau Veritas in 2005 and has held various sales, marketing, and operational leadership roles in Consumer Product Services. Catherine will continue to connect Consumer Products & Technology Product Lines, as Executive Vice-President, Consumer Products Services.


Laurent Louail, appointed Executive Vice-President Chief Performance Officer, joined Bureau Veritas in 1995 and has held multiple leadership roles across the company. His most recent roles were Executive Vice-President, Commodities, Industry & Facilities in Southwest Europe, before becoming Executive Vice-President, Global Business Lines & Performance.


Juliano Cardoso remains Executive Vice-President Corporate Development & Sustainability. He joined Bureau Veritas in 1999 and has held leadership roles across the company. Juliano will continue to lead our corporate development and sustainability efforts in his current role as Executive Vice-President, Corporate Development & Sustainability.


Philipp Karmires remains Executive Vice-President Chief Digital & Innovation Officer. He is a senior executive with over 20 years of experience in digital transformation, enterprise software and product innovation. Philipp joined Bureau Veritas in 2024 and will continue to lead the DxT (Digital & Technology) function as Executive Vice-President, Chief Digital & Innovation Officer.


François Chabas remains Executive Vice-President Chief Financial Officer. He joined Bureau Veritas in 2003, holding finance roles with increasing responsibility before becoming Chief Financial Officer in 2014. François will continue to lead the finance function as Executive Vice-President, Finance.


Maria Lorente Fraguas remains Executive Vice-President Chief People Officer. She joined Bureau Veritas in 2024 after holding senior operational and human resources roles in international companies across multiple countries. Maria will continue to lead the people function as Executive Vice-President, Chief People Officer.


Béatrice Place-Faget remains Executive Vice-President Legal & Internal Audit. She joined Bureau Veritas in 2020 after serving as general counsel for other companies in France. Béatrice will continue to lead the legal and compliance function as Executive Vice-President, Legal affairs & Internal Audit.


Our information is certified with blockchain technology.

Check that this press release is genuine at www.wiztrust.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250618391984/en/



Permalink

https://www.aetoswire.com/en/news/1806202547470


Contacts

ANALYST/INVESTOR CONTACTS

Laurent Brunelle

+33 (0)1 55 24 76 09

laurent.brunelle@bureauveritas.com


Colin Verbrugghe

+33 (0)1 55 24 77 80

colin.verbrugghe@bureauveritas.com


MEDIA

Anette Rey

+33 (0)6 69 79 84 88

anette.rey@bureauveritas.com


Martin Bovo

+33 (0) 6 14 46 79 94

martin.bovo@bureauveritas.com


Karine Ansart

karine.ansart@bureauveritas.com


Inès Lagoutte

ines.lagoutte@bureauveritas.com